<span item_type="fundamental" item_id="c26f29e72990d186bae2d445946a0315" counter_id="ST/US/LVTX" env="prod"></span><span item_type="announcement" item_id="579898709889193986" env="prod"></span><p>Revenue: As of FY2025 Q3, the actual value is USD 0.</p><p>EPS: As of FY2025 Q3, the actual value is USD -0.27.</p><p>EBIT: As of FY2025 Q3, the actual value is USD -8.09 M.</p><p></p><h3>Segment Revenue</h3><ul><li><strong>Revenue from Contracts with Customers</strong>: No revenue was recognized for the nine months ended September 30, 2025, compared to $6.992 million for the same period in 2024, primarily due to the absence of milestone payments from Pfizer in 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1840748/000110465925107725/lvtx-20250930x10q.htm"></span></li></ul><h3>Operational Metrics</h3><ul><li><strong>Net Loss</strong>: The net loss for the nine months ended September 30, 2025, was $19.306 million, compared to $21.237 million for the same period in 2024, reflecting a decrease of $1.931 million.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1840748/000110465925107725/lvtx-20250930x10q.htm"></span></li><li><strong>Research and Development Expenses</strong>: Decreased to $11.134 million for the nine months ended September 30, 2025, from $19.881 million in 2024, primarily due to the discontinuation of clinical trials.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1840748/000110465925107725/lvtx-20250930x10q.htm"></span></li><li><strong>General and Administrative Expenses</strong>: Increased to $11.296 million for the nine months ended September 30, 2025, from $9.881 million in 2024, mainly due to legal and professional fees associated with the XOMA Transaction.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1840748/000110465925107725/lvtx-20250930x10q.htm"></span></li></ul><h3>Cash Flow</h3><ul><li><strong>Net Cash Used in Operating Activities</strong>: $30.262 million for the nine months ended September 30, 2025, compared to $19.050 million in 2024, primarily due to changes in operating assets and liabilities.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1840748/000110465925107725/lvtx-20250930x10q.htm"></span></li><li><strong>Net Cash Provided by Investing Activities</strong>: $40.364 million for the nine months ended September 30, 2025, compared to $1.499 million in 2024, mainly due to maturities of investments.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1840748/000110465925107725/lvtx-20250930x10q.htm"></span></li></ul><h3>Unique Metrics</h3><ul><li><strong>Gain on Extinguishment of Borrowings</strong>: A gain of $5.203 million was recognized in 2025 due to the waiver of the remaining loan balance by RVO.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1840748/000110465925107725/lvtx-20250930x10q.htm"></span></li></ul><h3>Future Outlook and Strategy</h3><ul><li><strong>Core Business Focus</strong>: The company is focused on completing the XOMA Transaction, which is expected to close in the fourth quarter of 2025. The transaction involves a tender offer for all outstanding shares, with a cash amount plus one contingent value right per share.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1840748/000110465925107725/lvtx-20250930x10q.htm"></span></li><li><strong>Non-Core Business</strong>: The company is discontinuing all clinical studies and nonclinical research and development activities as part of the strategic review process and restructuring plan initiated in February 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1840748/000110465925107725/lvtx-20250930x10q.htm"></span></li></ul>

LAVA Therapeutics NV | 10-Q: FY2025 Q3 Revenue: USD 0